We have demonstrated that AAV-2 vectors can transduce human hepatocytes in vivo. However, AAV-mediated gene transfer is limited due to pre-existing humoral immunity and transgene expression is short-lived because of an immune response directed against the capsid containing hepatocytes. The goal of this project is to develop a novel class of human gene transfer vector based on adeno-associated virus (AAV) that combines high efficiency in vivo transduction of target tissues, with the capability to circumvent or overcome host immunologic responses in humans including the existence of neutralizing antibodies in the human population that may limit their efficacy. These novel vectors will be derived by 'molecular evolution' of DNA from an array of naturally occurring AAV serotypes. This array will comprise previously reported AAV variants from humans and primates, as well as new AAVs of non-primate origin whose isolation is our primary specific aim. The genomes of the various AAV isolates will be 'shuffled' to generate a DNA pool from which we will then generate a library of recombinant AAV particles having unique capsids. It is our idea that those capsids will combine the low reactivity with human sera as it is typical for non-primate AAVs, with the high efficiency of in vivo transduction as reported for primate/human AAVs. This AAV library will then be mixed with antibodies raised against primate/human AAV serotypes and used to transduce mouse liver in vivo. It is hoped that this form of selective pressure will enable us to isolate AAV capsid sequences allowing efficient in vivo transduction while evading neutralization from pre-existing immunity. We plan to test these new vectors in animal models of hemophilia. Our ultimate goal is to utilize any sequences that we can identify for development of novel improved AAV vectors for use in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01HL066948-06
Application #
7154979
Study Section
Special Emphasis Panel (ZHL1-CSR-I (M1))
Project Start
2005-09-29
Project End
2006-08-31
Budget Start
2005-09-29
Budget End
2007-08-31
Support Year
6
Fiscal Year
2005
Total Cost
$414,710
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Margaritis, Paris (2010) Long-term expression of canine FVIIa in hemophilic dogs. Thromb Res 125 Suppl 1:S60-2
Margaritis, Paris; Roy, Elise; Aljamali, Majed N et al. (2009) Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 113:3682-9
Bedi, Maninder S; Alvarez Jr, Rene J; Kubota, Toru et al. (2008) Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support. Clin Transl Sci 1:245-8
Aljamali, Majed N; Margaritis, Paris; Schlachterman, Alexander et al. (2008) Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 118:1825-34
Akache, Bassel; Grimm, Dirk; Shen, Xuan et al. (2007) A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 15:330-9
Chen, Jian; Wu, Qi; Yang, Pingar et al. (2006) Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther 13:260-9
Bedi, Maninder; McNamara, Dennis; London, Barry et al. (2006) Genetic susceptibility to atrial fibrillation in patients with congestive heart failure. Heart Rhythm 3:808-12
Grimm, Dirk; Pandey, Kusum; Nakai, Hiroyuki et al. (2006) Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 80:426-39
Inagaki, Katsuya; Fuess, Sally; Storm, Theresa A et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14:45-53
Manno, Catherine S; Arruda, Valder R; Pierce, Glenn F et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-7

Showing the most recent 10 out of 36 publications